Skip to content

A Pharmacokinetic Study of Nutri-PEITC Jelly in Head and Neck Cancer Survivors

A Pharmacokinetic Study of PEITC in Nutri-Jelly in Healthy Head and Neck Cancer Survivors

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03700983
Enrollment
12
Registered
2018-10-09
Start date
2016-08-06
Completion date
2018-09-30
Last updated
2018-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer

Brief summary

This research aims to evaluate the absorption and elimination profile of a bioactive compound PEITC in the matrix of Nutri-jelly - a novel edible nutritious gel. Thus, the investigators conducted a pharmacokinetic study in 12 head and neck cancer survivors. After consumed a serving of Nutri-jelly containing 20 mg PEITC, plasma levels of PEITC at 0, 1, 2, 3, 4, 6, 8, 12 and 24 hours were specifically measured by ammonia derivatization and analyzed by liquid chromatography-mass spectrometry (LC-MS/MS). Non-compartmental pharmacokinetic analysis was performed.

Detailed description

β-phenylethyl isothiocyanate (PEITC) is a phytochemical found in cruciferous vegetables with anti-cancer properties in vitro and in vivo. However, its pharmacokinetic profile in cancer survivors were unknown. A pharmacokinetic study was conducted in head and neck cancer survivors to evaluate the absorption and elimination profile of PEITC in the matrix of Nutri-jelly - a novel edible nutritious gel. Twelve head and neck cancer survivors consumed a serving of Nutri-jelly containing 20 mg PEITC. Plasma levels of PEITC at 0, 1, 2, 3, 4, 6, 8, 12 and 24 hours were specifically measured by ammonia derivatization and analyzed by LC-MS/MS. Non-compartmental pharmacokinetic analysis was performed. Pharmacokinetic parameters including Cmax, Tmax, half-life, clearance were analyzed.

Interventions

DIETARY_SUPPLEMENTNutri-PEITC jelly

an edible, easily to swallow nutritious gel containing a bioactive compound PEITC

Sponsors

Maha Vajiralongkorn Thanyaburi Hospital
CollaboratorUNKNOWN
Mahidol University
CollaboratorOTHER
Srinakharinwirot University
CollaboratorOTHER
Dental Innovation Foundation Under Royal Patronage
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

Head and neck cancer survivors - patients who had been diagnosed with cancer of lip, oral cavity, oropharynx and nasopharynx, received treatment and the oncologists had defined them as complete remission, and having normal physical exam and blood biochemistry

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* age 20 or above * Diagnosed with Head and neck cancer * Completed radiation or chemotherapy since at least 4 weeks ago * normal physical exam * Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2 * Life expectancy \> 3 months * Normal kidney function evidenced by serum creatinine, blood urea nitrogen (BUN), no kidney stone, no history of renal dialysis * Normal liver function evidenced by serum bilirubin, aspartate transaminase (AST), alanine amino transferase (ALT) * not pregnant or breastfeeding * no psychiatric symptoms * normal vital sign and normal blood chemistry including complete blood count CBC) * provide voluntary inform consent

Exclusion criteria

* unable to communicate * reject to take Nutri-jelly * unable to refrain from vegetable intake for 3 days prior to the test * take paracetamol during 2 days prior to the test * body weight less than 35 kg or higher than 65 kg * oral infection such as Candidiasis interfering with normal oral intake

Design outcomes

Primary

MeasureTime frameDescription
Maximum plasma concentration (Cmax) of PEITCDay 0 - Day 1Plasma concentration of PEITC during 24 hours after intake of Nutri-jelly will be measured and the highest concentration will be identified.
Time to reach maximum concentration (Tmax)Day 0 - Day 1The duration to reach maximum plasma concentration of PEITC will be calculated.

Secondary

MeasureTime frameDescription
Area under the curve of plasma concentration of PEITC and timeDay 0 - Day 1Graph between plasma concentration and time will be plotted. The area under the curve will be calculated.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026